Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epcoritamab plus venetoclax in relapsed/refractory CLL or SLL
ACTRN12625000732482Phase 2Recruiting
- Sponsor
- Australasian Leukaemia & Lymphoma Group
- Start
- Jun 2026
- Modality
- Small Molecules, T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 4
01
Overview
Phase 2, randomised, open-label trial of epcoritamab and venetoclax in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) (2 arms), sponsored by Australasian Leukaemia & Lymphoma Group. Primary endpoint: Undetectable minimal residual disease in bone marrow without progression. Started Jun 2026; status: recruiting.
02
Drugs
epcoritamabvenetoclax
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on ACTRN12625000732482.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12625000732482.